Literature DB >> 17570107

Human herpesvirus 8 seroprevalence among prostate cancer case patients and control subjects.

F J Jenkins1, R B Hayes, A Jackson, G Pizza, G Mbisa, D Whitby, J J Goedert.   

Abstract

To investigate a possible association between human herpesvirus 8 (HHV-8) and prostate cancer, we evaluated HHV-8 seroprevalence in 2 case-control studies. HHV-8 antibodies were detected by immunofluorescence with cells expressing lytic viral proteins and by enzyme immunoassays with recombinant viral structural protein (K8.1) and latent protein (latency-associated nuclear antigen-1; open reading frame 73), respectively. HHV-8 seroprevalence tended to be lower in patients with prostate cancer than in control subjects, but there was no significant difference in either study. These data imply that HHV-8 is not a major prevalent cause of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17570107     DOI: 10.1086/518790

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

Review 1.  A review of African American-white differences in risk factors for cancer: prostate cancer.

Authors:  Irina Mordukhovich; Paul L Reiter; Danielle M Backes; Leila Family; Lauren E McCullough; Katie M O'Brien; Hilda Razzaghi; Andrew F Olshan
Journal:  Cancer Causes Control       Date:  2010-12-24       Impact factor: 2.506

2.  Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.

Authors:  Siobhan Sutcliffe; Cathee Till; Frank J Jenkins; Charlotte A Gaydos; Phyllis J Goodman; Ashraful M Hoque; Ann W Hsing; Ian M Thompson; William G Nelson; Angelo M De Marzo; Elizabeth A Platz
Journal:  Cancer Causes Control       Date:  2014-10-31       Impact factor: 2.506

3.  Human herpesvirus 8 infection is associated with prostate cancer among IFNL4-ΔG carriers.

Authors:  Frank J Jenkins; Tsion Z Minas; Wei Tang; Tiffany H Dorsey; Stefan Ambs
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-04-25       Impact factor: 5.554

4.  Sexually transmissible infections and prostate cancer risk.

Authors:  Wen-Yi Huang; Richard Hayes; Ruth Pfeiffer; Raphael P Viscidi; Francis K Lee; Yun F Wang; Douglas Reding; Denise Whitby; John R Papp; Charles S Rabkin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

Review 5.  Inflammation and prostate cancer: a focus on infections.

Authors:  Siobhan Sutcliffe; Elizabeth A Platz
Journal:  Curr Urol Rep       Date:  2008-05       Impact factor: 3.092

6.  Four-antigen mixture containing v-cyclin for serological screening of human herpesvirus 8 infection.

Authors:  Peter D Burbelo; Hannah P Leahy; Sandra Groot; Lisa R Bishop; Wendell Miley; Michael J Iadarola; Denise Whitby; Joseph A Kovacs
Journal:  Clin Vaccine Immunol       Date:  2009-03-04

7.  Herpes simplex virus type 2 or human herpesvirus 8 infection and prostate cancer risk: A meta-analysis.

Authors:  Xiaoxiao Ge; Xiao Wang; Peng Shen
Journal:  Biomed Rep       Date:  2013-03-19

Review 8.  Antibody-profiling technologies for studying humoral responses to infectious agents.

Authors:  Peter D Burbelo; Kathryn H Ching; Emily R Bush; Brian L Han; Michael J Iadarola
Journal:  Expert Rev Vaccines       Date:  2010-06       Impact factor: 5.217

9.  A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago.

Authors:  Alicia C McDonald; Frank J Jenkins; Clareann H Bunker; John W Wilson; Alan L Patrick; Joel L Weissfeld
Journal:  Infect Agent Cancer       Date:  2011-12-07       Impact factor: 2.965

10.  Rapid Multiplexed Immunoassay for Detection of Antibodies to Kaposi's Sarcoma-Associated Herpesvirus.

Authors:  Cathy Logan; Kathryn Todorof; Suzanne P Fiorillo; Thomas B Campbell; John H Elder; Margaret Borok; Ivy Gudza; Lovemore Gwanzura; Buxton Ndemera; Michael J Lochhead; Constance A Benson; Robert T Schooley
Journal:  PLoS One       Date:  2016-09-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.